Bristol Myers Squibb Co
- Last sale
- Nov 12, 2026 · -0.92%
- Market cap
- $127.43B
- 2.04B shares
- Filings
- 1,071
Q3 2026−0.2% FY25 yoy
Q3 2026N/M FY25 yoy
Q1 2012
—Q3 2026derived−7.9% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−1.3% FY25 yoy
- $127.43B
- 13.8×
- 2.5×
- 5.4×
- 7.29%
- 4.02%
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $48,194,000,000 | reported | |
| FY 2024 | 2024-12-31 | $48,300,000,000 | reported | |
| FY 2023 | 2023-12-31 | $45,006,000,000 | reported | |
| FY 2022 | 2022-12-31 | $46,159,000,000 | reported | |
| FY 2021 | 2021-12-31 | $46,385,000,000 | reported | |
| FY 2020 | 2020-12-31 | $42,518,000,000 | reported | |
| FY 2019 | 2019-12-31 | $26,145,000,000 | reported | |
| FY 2018 | 2018-12-31 | $22,561,000,000 | reported | |
| FY 2017 | 2017-12-31 | $20,776,000,000 | reported | |
| FY 2016 | 2016-12-31 | $19,427,000,000 | reported | |
| FY 2015 | 2015-12-31 | $16,560,000,000 | reported | |
| FY 2014 | 2014-12-31 | $15,879,000,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $5.05B | $0.00 | $5.05B | $2.49 | 2.04B sh | +0.4% | 39.3% |
| FY2024 | $4.86B | $0.00 | $4.86B | $2.42 | 2.03B sh | +0.4% | 34.9% |
| FY2023 | $4.74B | $5.16B | $9.90B | $2.31 | 2.02B sh | −3.6% | 78.2% |
| FY2022 | $4.63B | $8.00B | $12.64B | $2.19 | 2.10B sh | −3.7% | 105.7% |
| FY2021 | $4.40B | $6.29B | $10.68B | $2.01 | 2.18B sh | −2.7% | 70.1% |
Segments
LineFY2025ShareChange
United States$33.28B69%−2.4%
International$13.83B29%+4.8%
Other$1.09B2.3%+9.1%
International———
International———
Rest of World———
Total$48.19B
Pharmaceutical preparations
Bristol Myers Squibb Co is the 7th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
JNJJohnson & Johnson$94.2B6.0%28.5%$682.6BLLYEli Lilly & Co$65.2B44.7%31.7%$1.3TMRKMerck & Co., Inc.$65.0B1.3%28.1%$362.3BPFEPfizer Inc$62.6B1.6%12.4%$164.3BABBVAbbVie Inc.$61.2B8.6%6.9%$520.5BAZNAstraZeneca PLC$58.7B8.6%17.4%—
BMYBristol Myers Squibb Co (this company)$48.2B0.2%14.6%$127.4B
ABTAbbott Laboratories$44.3B5.7%14.7%$185.8BUPCUniverse Pharmaceuticals INC$17.9B22.4%20.6%—Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Bristol Myers Squibb Co · CIK 14272 · Engraved from SEC EDGAR